CELL-EASY
Cell-Easy, a start-up based in Toulouse specialized in stem cell therapy, announces today the signature of an agreement with the University Hospital Centre in Toulouse, as well as securing the authorization to open a pharmaceutical manufacturing plant dedicated to the production of stem cells - a first in France. This follows the announcement made last December of raising 1M€ capital investment.
Thanks to its innovative mass scale stem cells manufacturing process, Cell Easy aims to develop regenerative medicine through therapeutic solutions based on Advanced Therapy Medicinal Products compatible with affordable access for millions of patients.
The start-up has now signed a first partnership with the University Hospital Center in Toulouse and will be producing Mesenchymal stem cells (or stromal cells) sourced from qualified fat tissue in accordance with good manufacturing practices. A first clinical trial is on its way to fight against Alzheimer disease.
« Our ambition is to industrialize our proprietary stem cell manufacturing process to make Cell Therapy accessible to the largest number possible of patients. The aim is to cut costs by ten and increase production capacity beyond 100 0000 doses /year. » explains Pierre Monsan, DG of Cell-Easy and Founder of Toulouse White Biotechnology (TWB).
« Today, stem cell-based treatments represent a major therapeutic hope. What has been set up here is very much the expression of the way the University Hospital Centre approaches the development of innovative technologies, therapies and organizations that support new therapies founded on cross fertilization of talent and expertise . » says Marc Penaud, Executive Manager of the University Hospital Center in Toulouse.
Furthermore, the French Medicines Agency, also gave Cell-Easy the authorization to open a pharmaceutical plant to manufacture stem cell batches at large scale, in accordance with GMP (Good Manufacturing Practices) standards. This authorization makes Cell-Easy the only private pharmaceutical organization able to manufacture stem cells in France on an industrial scale. This firmly puts Cell-Easy on the European stage.
Capital investment is being secured to finance the quick implementation of their strategy in France but also in Europe where patients’ needs are high.
Cell-Easy will now be able to manufacture stem cells batches for industrial partners and is one of the world’s precursors in cell therapy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
Primient to Acquire Full Ownership of Primient Covation, LLC14.1.2026 16:00:00 CET | Press release
Primient, a global leader in biomanufacturing, announced today it has agreed to purchase the remaining ownership interest in Primient Covation, LLC (“Primient Covation”), establishing Primient as the sole owner of the company and marking an exciting new chapter in Primient’s growth in the bioeconomy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114344080/en/ This acquisition is the next step of Primient’s strategy to strengthen Primient’s leadership position in biomanufacturing and builds upon recent announcements, including Primient’s partnership with Sustainea and the creation of the iPROOF venture. Primient Covation stands as a leading force in the U.S. biomanufacturing sector, distinguished by its broad range of biomanufacturing and fermentation expertise. The company was founded in 2000 to supply a variety of end markets, including cosmetics and personal care, textiles, fashion, coatings, functional fluids, and oth
BitGo Holdings annoncerer lancering af børsintroduktion14.1.2026 15:53:00 CET | Pressemeddelelse
BitGo Holdings, Inc. ("BitGo"), som er en virksomhed inden for digital infrastruktur til aktiver, annoncerede i dag lanceringen af sin børsintroduktion af 11.821.595 aktier af klasse A-stamaktier i henhold til en registreringserklæring på formular S-1, der er indsendt til det amerikanske finanstilsyn, U.S. Securities and Exchange Commission (kendt som "SEC"). Udbuddet omfatter 11.000.000 aktier af klasse A-stamaktier udbudt af BitGo samt 821.595 aktier af klasse A-stamaktier udbudt af visse eksisterende aktionærer i BitGo. BitGo vil ikke modtage noget provenu fra salget af aktier fra de sælgende aktionærer i forbindelse med udbuddet. I forbindelse med udbuddet har BitGo til hensigt at give konsortiet af garantibanker en 30-dages option til at købe op til yderligere 1.770.000 aktier af klasse A-stamaktier. Den forventede introduktionskurs i forbindelse med børsnoteringen vil ligge mellem 15 og 17 USD pr. aktie. BitGo har ansøgt om at få sine klasse A-stamaktier optaget til handel på New
Paysafe Research: First-Time and Casual Betting to Surge for 2026 World Cup14.1.2026 15:10:00 CET | Press release
60% of World Cup fans plan to bet online, marking a major revenue opportunity for online sportsbooks with optimized payments tailored to local preferences 19% of global consumers with an interest in following this summer’s 2026 World Cup plan to place their first ever online bet during the soccer tournament, according to research issued today by leading payments platform Paysafe (NYSE: PSFE). The company’s All the Ways Players Pay: World Cup 2026 report also indicates that brand reputation and offering flexible, reliable payments will be crucial for online sportsbooks when converting and retaining new and experienced bettors alike. With the World Cup returning to North America for the first time since 1994, there is strong appetite for online wagering in the host countries of the U.S., Mexico, and Canada as well as in Europe and Latin America, with 60% of global fans planning to bet. Across U.S. states where sports betting is legal, 62% intend to wager, with 29% placing their first eve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom